With 2024 well under way, influential conferences in London have given a barometer reading on the conditions in the European biopharma market, reports Richard Staines.
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats.
In the final instalment of the five-part, festive series of the pharmaphorum podcast, host Nicole Raleigh speaks with Cencora’s SVP of international commercialisation, Sandra Anderson, and
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.